Abicipar pegol—a novel anti-VEGF therapy with a long duration of action

Abicipar pegol—a novel anti-VEGF therapy with a long duration of action

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eye (London) 2020-04, Vol.34 (4), p.605-606
Hauptverfasser: Moisseiev, Elad, Loewenstein, Anat
Format: Artikel
Sprache:eng
Schlagworte:
692/699/3161
692/699/3161/3175
Editorial
Laboratory Medicine
Life Sciences & Biomedicine
Medicine
Medicine & Public Health
Ophthalmology
Pharmaceutical Sciences/Technology
Science & Technology
Surgery
Surgical Oncology
Vascular endothelial growth factor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 606
container_issue 4
container_start_page 605
container_title Eye (London)
container_volume 34
creator Moisseiev, Elad
Loewenstein, Anat
description
doi_str_mv 10.1038/s41433-019-0584-y
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_journals_2382601288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2382601288</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-c811f12ef2c04341e528c7ee4ef40c4826c0019ad71f23cf8dd368132744b78f3</originalsourceid><addsrcrecordid>eNqNkd9qFDEUxoModq0-gDcS8KYgo_k7ydwIZWlroeCNinchm0l2U2aTMcm07J0P4RP6JGaduv4BRQjkwPl9J-fLB8BTjF5iROWrzDCjtEG4axCXrNndAwvMRNtwxtl9sEAdRw0h5OMReJTzNUK1KdBDcEQxp0J2dAEuT1fe-FEnONp1HL5-_qJhiDd2gDoU33w4uziHZWOTHnfw1pcN1HCIYQ37KeniY4DRQW321WPwwOkh2yd39zF4f372bvmmuXp7cbk8vWoM62RpjMTYYWIdMYhRhi0n0ghrmXUMGSZJa-qene4FdoQaJ_uethJTIhhbCenoMXg9zx2n1db2xoaS9KDG5Lc67VTUXv3eCX6j1vFGCdJyRmUdcHI3IMVPk81FbX02dhh0sHHKipCOs5Z2glX0-R_odZxSqPYUYYKj-sGt-CdFqyGEidw_i2fKpJhzsu6wMkZqH6ea41TVvdrHqXZV8-xXrwfFj_wqIGfg1q6iy8bbYOwBQwhxguuhtUJ46cv3zJZxCqVKX_y_tNJkpnMlwtqmnx7_vv43BSjLOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2382601288</pqid></control><display><type>article</type><title>Abicipar pegol—a novel anti-VEGF therapy with a long duration of action</title><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Moisseiev, Elad ; Loewenstein, Anat</creator><creatorcontrib>Moisseiev, Elad ; Loewenstein, Anat</creatorcontrib><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/s41433-019-0584-y</identifier><identifier>PMID: 31537893</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/3161 ; 692/699/3161/3175 ; Editorial ; Laboratory Medicine ; Life Sciences &amp; Biomedicine ; Medicine ; Medicine &amp; Public Health ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Science &amp; Technology ; Surgery ; Surgical Oncology ; Vascular endothelial growth factor</subject><ispartof>Eye (London), 2020-04, Vol.34 (4), p.605-606</ispartof><rights>The Royal College of Ophthalmologists 2019</rights><rights>2019© The Royal College of Ophthalmologists 2019</rights><rights>The Royal College of Ophthalmologists 2019.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>24</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000521521300001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c498t-c811f12ef2c04341e528c7ee4ef40c4826c0019ad71f23cf8dd368132744b78f3</citedby><cites>FETCH-LOGICAL-c498t-c811f12ef2c04341e528c7ee4ef40c4826c0019ad71f23cf8dd368132744b78f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265438/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265438/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,729,782,786,887,27933,27934,28257,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31537893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moisseiev, Elad</creatorcontrib><creatorcontrib>Loewenstein, Anat</creatorcontrib><title>Abicipar pegol—a novel anti-VEGF therapy with a long duration of action</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>EYE</addtitle><addtitle>Eye (Lond)</addtitle><subject>692/699/3161</subject><subject>692/699/3161/3175</subject><subject>Editorial</subject><subject>Laboratory Medicine</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Science &amp; Technology</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Vascular endothelial growth factor</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkd9qFDEUxoModq0-gDcS8KYgo_k7ydwIZWlroeCNinchm0l2U2aTMcm07J0P4RP6JGaduv4BRQjkwPl9J-fLB8BTjF5iROWrzDCjtEG4axCXrNndAwvMRNtwxtl9sEAdRw0h5OMReJTzNUK1KdBDcEQxp0J2dAEuT1fe-FEnONp1HL5-_qJhiDd2gDoU33w4uziHZWOTHnfw1pcN1HCIYQ37KeniY4DRQW321WPwwOkh2yd39zF4f372bvmmuXp7cbk8vWoM62RpjMTYYWIdMYhRhi0n0ghrmXUMGSZJa-qene4FdoQaJ_uethJTIhhbCenoMXg9zx2n1db2xoaS9KDG5Lc67VTUXv3eCX6j1vFGCdJyRmUdcHI3IMVPk81FbX02dhh0sHHKipCOs5Z2glX0-R_odZxSqPYUYYKj-sGt-CdFqyGEidw_i2fKpJhzsu6wMkZqH6ea41TVvdrHqXZV8-xXrwfFj_wqIGfg1q6iy8bbYOwBQwhxguuhtUJ46cv3zJZxCqVKX_y_tNJkpnMlwtqmnx7_vv43BSjLOA</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Moisseiev, Elad</creator><creator>Loewenstein, Anat</creator><general>Nature Publishing Group UK</general><general>Springer Nature</general><general>Nature Publishing Group</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200401</creationdate><title>Abicipar pegol—a novel anti-VEGF therapy with a long duration of action</title><author>Moisseiev, Elad ; Loewenstein, Anat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-c811f12ef2c04341e528c7ee4ef40c4826c0019ad71f23cf8dd368132744b78f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/699/3161</topic><topic>692/699/3161/3175</topic><topic>Editorial</topic><topic>Laboratory Medicine</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Science &amp; Technology</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moisseiev, Elad</creatorcontrib><creatorcontrib>Loewenstein, Anat</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moisseiev, Elad</au><au>Loewenstein, Anat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abicipar pegol—a novel anti-VEGF therapy with a long duration of action</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><stitle>EYE</stitle><addtitle>Eye (Lond)</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>34</volume><issue>4</issue><spage>605</spage><epage>606</epage><pages>605-606</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31537893</pmid><doi>10.1038/s41433-019-0584-y</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0950-222X
ispartof Eye (London), 2020-04, Vol.34 (4), p.605-606
issn 0950-222X
1476-5454
language eng
recordid cdi_proquest_journals_2382601288
source Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central; Alma/SFX Local Collection
subjects 692/699/3161
692/699/3161/3175
Editorial
Laboratory Medicine
Life Sciences & Biomedicine
Medicine
Medicine & Public Health
Ophthalmology
Pharmaceutical Sciences/Technology
Science & Technology
Surgery
Surgical Oncology
Vascular endothelial growth factor
title Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T13%3A41%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abicipar%20pegol%E2%80%94a%20novel%20anti-VEGF%20therapy%20with%20a%20long%20duration%20of%20action&rft.jtitle=Eye%20(London)&rft.au=Moisseiev,%20Elad&rft.date=2020-04-01&rft.volume=34&rft.issue=4&rft.spage=605&rft.epage=606&rft.pages=605-606&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/s41433-019-0584-y&rft_dat=%3Cproquest_webof%3E2382601288%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2382601288&rft_id=info:pmid/31537893&rfr_iscdi=true